Chart-Typ:
Zeitraum:
| InflaRx N.V.: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones | Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness... ► Artikel lesen |
| InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen |
| Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For InflaRx? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen |
| Atossa Therapeutics Inc: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives | Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's... ► Artikel lesen |
| XFRA 7300,B0Y,YAG: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZEROSTACK CORP.... ► Artikel lesen |
| XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement | TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical... ► Artikel lesen |
| RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.